<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388960</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC Protocol 08062</org_study_id>
    <secondary_id>2006-001956-11</secondary_id>
    <nct_id>NCT00388960</nct_id>
    <nct_alias>NCT00424073</nct_alias>
  </id_info>
  <brief_title>Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to document the activity and safety of single agent amrubicin,
      amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line
      treatment in extensive disease small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)</measure>
    <time_frame>Until Disease Progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Until 30 days after last protocol treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Until disease progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until death</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Amrubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amrubicin 45mg/m&lt;2&gt; IV days 1, 2, 3 of each 21-day cycle until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amrubicin plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amrubicin 40mg/m&lt;2&gt; IV days 1, 2, 3 plus cisplatin 60mg/m&lt;2&gt; IV day 1 of each 21-day cycle until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin plus etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 75mg/m&lt;2&gt; IV day 1 plus etoposide 100mg/m&lt;2&gt; IV day 1 and 200mg/m&lt;2&gt; orally days 2, 3 or etoposide 100mg/m&lt;2&gt; IV days 1, 2, 3 each 21-day cycle until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amrubicin</intervention_name>
    <description>Amrubicin 45mg/m&lt;2&gt; IV days 1, 2 3 of each 21-day cycle until disease progression.
Amrubicin 40mg/m&lt;2&gt; IV days 1, 2, 3 plus cisplatin 60mg/m&lt;2&gt; day 1 of each 21-day cycle until disease progression.</description>
    <arm_group_label>Amrubicin</arm_group_label>
    <arm_group_label>Amrubicin plus Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Amrubicin 40mg/m&lt;2&gt; IV days 1, 2, 3 plus Cisplatin 60mg/m&lt;2&gt; day 1 of each 21-day cycle until disease progression.
Cisplatin 75mg/m&lt;2&gt; IV day 1 plus etoposide 100mg/m&lt;2&gt; IV day 1 and 200mg/m&lt;2&gt; orally days 2, 3 or etoposide 100mg/m&lt;2&gt; IV days 1, 2, 3 of each 21-day cycle until disease progression.</description>
    <arm_group_label>Amrubicin plus Cisplatin</arm_group_label>
    <arm_group_label>Cisplatin plus etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Cisplatin 75mg/m&lt;2&gt; IV day 1 plus etoposide 100mg/m&lt;2&gt; IV day 1 and 200mg/m&lt;2&gt; orally days 2, 3 or etoposide 100mg/m&lt;2&gt; IV days 1, 2, 3 of each 21-day cycle until disease progression.</description>
    <arm_group_label>Cisplatin plus etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically proven small cell lung cancer

          -  Extensive disease

          -  Measurable disease

          -  World Health Organization (WHO) performance status 0-2

          -  Age 18 years or older

          -  Normal baseline cardiac function

          -  No prior systemic chemotherapy for small cell lung cancer

          -  Adequate organ function including bone marrow, kidney, and liver

          -  No history of interstitial lung disease or pulmonary fibrosis

          -  No history of prior malignancy unless patient has been disease free for greater than 5
             years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix

          -  No pregnancy or breast feeding; patients of child-bearing potential must agree to use
             an appropriate method of contraception

          -  Written informed consent before randomization

        Exclusion criteria:

          -  Pre-existing peripheral neuropathy (greater than Grade 1, CTCAE version 3.0)

          -  Uncontrolled or severe cardiovascular disease

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden Hospital, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Domaine Universitaire du Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>1BE</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente - Dept of Pulmonary Diseases</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Kliniek</name>
      <address>
        <city>Zwolle</city>
        <zip>8001</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk - Dept Radiotherapy</name>
      <address>
        <city>Gdansk</city>
        <zip>80211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Bebington</city>
        <state>Merseyside</state>
        <zip>CH684JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Dundee - Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>D01 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital, London</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital Lung Unit</name>
      <address>
        <city>Sutton</city>
        <zip>(Surrey) SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.</citation>
    <PMID>21684151</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2006</study_first_submitted>
  <study_first_submitted_qc>October 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <disposition_first_submitted>May 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 5, 2012</disposition_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>amrubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Amrubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

